Jupiter Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
AIM
OAG
GP
SOCM
Jupiter Wealth Management's CRSP Position: Q1 2026 in Review
Jupiter Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 8,500 shares worth $448K. The position accounts for 0.18% of the portfolio, ranked #69.
Jupiter Wealth Management first reported a position in CRSP in Q1 2019 and has held it in 29 quarters since. The position peaked at $1.99M in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Jupiter Wealth Management held 8,500 shares of CRISPR Therapeutics worth $448K as of Q1 2026.
- Jupiter Wealth Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
- CRISPR Therapeutics made up 0.18% of Jupiter Wealth Management's portfolio in Q1 2026, its #69 holding.
- Jupiter Wealth Management first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 29 quarters since.
- Jupiter Wealth Management's CRISPR Therapeutics position peaked at $1.99M in Q4 2020.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Jupiter Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.